PRLog - Feb. 1, 2010 - SUNDERLAND, U.K. -- Squeezed by escalating R&D costs, Onyx Scientific predicts the pharmaceutical industry will accelerate their strategy to outsource non-core chemistry services to trusted contract laboratories and will no longer use contract services simply as a tactic to overcome near-term capacity shortage.
Contract Research Organisation
Onyx Scientific, the highly qualified chemical services company is witnessing, first-hand, the accelerated trend within large pharma and biotechs to form sustainable outsourcing partnerships for chemistry services, such as: custom synthesis, process development, lead optimization, GMP synthesis and scale up, automated salt selection, polymorphism studies/screening and solid state analysis.
Characterized by high risk – just 1 in 20,000 compounds become a pharmaceutical;
Onyx Scientific has structured its expertise-rich organisation to be creatively involved in the drug development process. Without this approach their services would lead to a commodity offering, rather than the opportunity to generate intellectual property. Green chemistry processes also serve to differentiate Onyx in their shared goal to reduce the environmental footprint of the industry.
Of equal significance is Onyx Scientifics’
Recognised as transformational, pharmaceutical outsourcing has taken the industry from its stand-alone company model to a fully integrated pharmaceutical network. Within this model, Onyx Scientific is well placed to provide unmatched chemical services to both the late discovery and early phases of new drug development. Uniquely, Onyx successfully combines integrated manufacturing and development services with solid-state analysis services. This winning combination assures optimal development of new pharmaceutical ingredients and maximum intellectual property return.
Routinely inspected by the MHRA, Onyx Scientifics’
# # #
Onyx Scientific has a highly experienced team of scientists with the expertise and enthusiasm required to meet the exacting demands of the pharmaceutical industry. They are specialists in both lead optimisation, custom synthesis and process development chemistry. 85% of their chemists are PhD qualified and are committed to excellence and rapid problem solving.